The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice
Open accessAbstract
Sphingolipids play a very important role in cell membrane formation, signal transduction, and plasma lipoprotein metabolism, all of which may well have an impact on the development of atherosclerosis. To investigate the relationship between sphingolipid metabolism and atherosclerosis, we utilized myriocin to inhibit mouse serine palmitoyl-CoA transferase (SPT), the key enzyme for sphingolipid biosynthesis. We injected 8-week-old apoE-deficient mice with myriocin (0.3 mg/kg/every other day, intraperitoneal) for 60 days. On a chow diet, myriocin treatment caused a significant decrease (50%) in liver SPT activity (p < 0.001), significant decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (54, 32, and 73%, respectively) (p < 0.0001), and a significant increase in plasma phosphatidylcholine levels (91%) (p < 0.0001). Plasma total cholesterol and triglyceride levels demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (42% in root and 36% in en face assays) (p < 0.01). On a high fat diet, myriocin treatment caused marked decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (59, 66, and 81%, respectively) (p < 0.0001), and a marked increase in plasma phosphatidylcholine levels (100%) (p < 0.0001). Total cholesterol and triglyceride demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (39% in root and 37% in en face assays) (p < 0.01). These results indicate that, apart from cholesterol levels, sphingolipids have an effect on atherosclerotic development and that SPT has proatherogenic properties. Thus, inhibition of SPT activity could be an alternative treatment for atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FUJITA, T., INOUE, K., YAMAMOTO, S., IKUMOTO, T., SASAKI, S., TOYAMA, R., CHIBA, K., HOSHINO, Y., & OKUMOTO, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.208 · Cited by 540
Miyake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T., & Kawasaki, T. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1827 · Cited by 536
Enzymes of Sphingolipid Metabolism: From Modular to Integrative Signaling
Hannun, Y. A., Luberto, C., & Argraves, K. M. (2001) · Biochemistry · doi:10.1021/bi002836k · Cited by 500
An update of the enzymology and regulation of sphingomyelin metabolism
Merrill, A. H., & Jones, D. D. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90211-f · Cited by 458
Murata, N., Sato, K., Kon, J., Tomura, H., YANAGITA, M., Kuwabara, A., Ui, M., & Okajima, F. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520809 · Cited by 407
Jiang, X.-C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L., & Tall, A. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5578 · Cited by 394
Self-citationPlasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease
Jiang, X.-C., Paultre, F., Pearson, T. A., Reed, R. G., Francis, C. K., Lin, M., Berglund, L., & Tall, A. R. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.12.2614 · Cited by 386
Self-citationSchissel, S. L., Tweedie-Hardman, J., Rapp, J. H., Graham, G., Williams, K. J., & Tabas, I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118934 · Cited by 341
Schissel, S. L., Schuchman, E. H., Williams, K. J., & Tabas, I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18431 · Cited by 275
Jiang, X.-C., Qin, S., Qiao, C., Kawano, K., Lin, M., Skold, A., Xiao, X., & Tall, A. R. (2001) · Nature Medicine · doi:10.1038/89977 · Cited by 256
Self-citation
Cited by
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232
Ceramides in insulin resistance and lipotoxicity
SUMMERS, S. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.11.002 · Cited by 848
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
A Ceramide-Centric View of Insulin Resistance
Chavez, J. A., & Summers, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.002 · Cited by 610
Holland, W. L., & Summers, S. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0025 · Cited by 595
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Pruett, S. T., Bushnev, A., Hagedorn, K., Adiga, M., Haynes, C. A., Sullards, M. C., Liotta, D. C., & Merrill, A. H. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800012-jlr200 · Cited by 433
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy
Park, T.-S., Hu, Y., Noh, H.-L., Drosatos, K., Okajima, K., Buchanan, J., Tuinei, J., Homma, S., Jiang, X.-C., Abel, E. D., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800147-jlr200 · Cited by 411
Self-citationCeramides and other sphingolipids as drivers of cardiovascular disease
Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A., & Holland, W. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00536-1 · Cited by 387
Emerging roles of lysophospholipids in health and disease
Tan, S. T., Ramesh, T., Toh, X. R., & Nguyen, L. N. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101068 · Cited by 371
Ceramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
Wang, D. D., Toledo, E., Hruby, A., Rosner, B. A., Willett, W. C., Sun, Q., Razquin, C., Zheng, Y., Ruiz-Canela, M., Guasch-Ferré, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024261 · Cited by 327
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Metabolic Messengers: ceramides
Summers, S. A., Chaurasia, B., & Holland, W. L. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0134-8 · Cited by 299
Altered Adipose and Plasma Sphingolipid Metabolism in Obesity
Samad, F., Hester, K. D., Yang, G., Hannun, Y. A., & Bielawski, J. (2006) · Diabetes · doi:10.2337/db06-0330 · Cited by 279
Roles and regulation of secretory and lysosomal acid sphingomyelinase
Jenkins, R. W., Canals, D., & Hannun, Y. A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.026 · Cited by 278
Geekiyanage, H., & Chan, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3883-11.2011 · Cited by 254
“, 2000) and inhibition of SPT decreases ceramide levels (Hojjati et al., 2005; Patil et al., 2007) and neuronal cell death by A (Cutler et al.”
BackgroundRuuth, M., Nguyen, S. D., Vihervaara, T., Hilvo, M., Laajala, T. D., Kondadi, P. K., Gisterå, A., Lähteenmäki, H., Kittilä, T., Huusko, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy319 · Cited by 180
“Inhibition of this enzyme in mice leads to the generation of SMdepleted lipoprotein particles.(31) After 10 weeks of a high-fat atherogenic diet combined with three intraperitoneal injections/week of myriocin or PBS (n = 11 per group), the animals were sacrificed.”
BackgroundSphingolipids and insulin resistance: the five Ws
Summers, S. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283373b66 · Cited by 136
Association of ceramides in human plasma with risk factors of atherosclerosis
Ichi, I., Nakahara, K., Miyashita, Y., Hidaka, A., Kutsukake, S., Inoue, K., Maruyama, T., Miwa, Y., Harada‐Shiba, M., Tsushima, M., et al. (2006) · Lipids · doi:10.1007/s11745-006-5041-6 · Cited by 96
Metadata
- Authors
- Hojjati, M. R., Li, Z., Zhou, H., Tang, S., Huan, C., Ooi, E., Lu, S., & Jiang, X.-C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 280
- Issue
- 11
- Pages
- 10284-10289
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2014959138
- Cited by
- 299
- References
- 31
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.